


are, the same or different, an amino acid residue having no strong acid residue, each reactive group in each side chain of the amino acid residue being able to be protected; A is a hydrogen atom, a protective group of N-terminus or an acid residue derived from a strong acid; and B is a hydroxyl group or a protective group of C-terminus.

4. (Amended) A polypeptide represented by the formula:



wherein R<sup>1</sup>'s are, the same or different, independently an amino acid residue introducing a strong acid residue thereinto via a reactive group of the amino acid residue; m is an integer of 3 to 30; A is a hydrogen atom, a protective group of N-terminus or an acid residue derived from a strong acid; and B is a hydroxyl group or a protective group of C-terminus.

5. (Amended) A polypeptide according to Claim 3, which is represented by the formula:



wherein m' is an integer of 4 to 20; R<sup>3</sup> is a tyrosine sulfate residue; each R<sup>2</sup> is an amino acid residue having no strong acid residue, each reactive group in each side chain of the amino acid residue being able to be protected; n is an integer of 1 to 26; and A and B are as defined in Claim 3.

6. (Amended) A combined product of a polypeptide having 3 to 30 acid residues derived from a strong acid and a substance having affinity for an analyte to be measured in a sample of

body fluids or cells.

7. (Amended) A compound comprising a polypeptide having 3 to 30 acid residues derived from a strong acid, the N-terminus of which is bound through a spacer to a maleimido group.

8. (Amended) A combined product of the compound of Claim 7 and a substance having a SH group and affinity for an analyte to be measured in a sample of body fluids or cells.

9. (Amended) A compound according to claim 7, which is represented by the formula:



wherein D is a maleimido group; E is a spacer; m is an integer of 3 to 30; at least three R<sup>4</sup>'s are, the same or different, independently an amino acid residue introducing a strong acid residue therein the via a reactive group of the amino acid residue, and the rest of R<sup>4</sup>'s are, the same or different, an amino acid residue having no strong acid residue, each reactive group in each side chain of the amino acid residue being able to be protected; and B is a hydroxyl group or a protective group of C-terminus.


10. (Amended) A compound according to claim 7, which is represented by the formula:



wherein D is a maleimido group; E is a spacer; R<sup>1</sup>'s are, the same or different, independently an

amino acid residue introducing a strong acid residue therein via a reactive group of the amino acid residue; m is an integer of 3 to 30; and B is a hydroxyl group or a protective group of C-terminus.

11. (Amended) A compound according to claim 7, which is represented by the formula:



(wherein D is a maleimido group; E is a spacer; m is an integer of 3 to 30; R<sup>1</sup>'s are, the same or different, independently an amino acid residue introducing a strong acid residue therein via reactive group of the amino acid residue, each reactive group in each side chain of the amino acid residue being able to be protected; n' is an integer of 1 to 27; and B is a hydroxyl group or a protective group of C-terminus.

12. (Amended) A reagent of measuring an analyte to be measured in a sample of body fluids or cells, which comprises a combined product of Claim 6 and a substance having affinity for the analyte.

13. (Amended) A reagent for measuring an analyte to be measured in a sample of body fluids or cells, which comprises a combined product of the compound of Claim 7 and a substance having a SH group and affinity for an analyte to be measured in a sample of body fluids or cells.

Please add new claims 22-26 as follows:

22. The polypeptide according to claim 3, which is

Ala-(Tyr(SO<sub>3</sub>H))<sub>4</sub>-β Ala (SEQ ID NO:11), Ala-(Tyr(SO<sub>3</sub>H))<sub>4</sub> (SEQ ID NO: 12), Ala-(Tyr(SO<sub>3</sub>H))<sub>5</sub>-β Ala (SEQ ID NO:13), Ala-(Tyr(SO<sub>3</sub>H))<sub>5</sub> (SEQ ID NO:14), Ala-(Tyr(SO<sub>3</sub>H))<sub>7</sub>-β Ala (SEQ ID NO: 15), Ala-(Tyr(SO<sub>3</sub>H))<sub>7</sub> (SEQ ID NO:16), Ala-(Tyr(SO<sub>3</sub>H))<sub>8</sub>-β Ala (SEQ ID NO:17), Ala-(Tyr(SO<sub>3</sub>H))<sub>8</sub> (SEQ ID NO:18), or Ala-(Tyr(SO<sub>3</sub>H))<sub>10</sub>-β Ala (SEQ ID NO:19).

23. The polypeptide according to claim 4, which is

(Ser-(SO<sub>3</sub>H))<sub>8</sub>-(Tyr(SO<sub>3</sub>H))<sub>5</sub> (SEQ ID NO:21).

24. The polypeptide according to claim 5, which is Ala-(Tyr(SO<sub>3</sub>H))<sub>4</sub> (SEQ ID NO:12), Ala-(Tyr(SO<sub>3</sub>H))<sub>5</sub> (SEQ ID NO:14), Ala-(Tyr(SO<sub>3</sub>H))<sub>7</sub> (SEQ ID NO:16) or Ala-(Tyr(SO<sub>3</sub>H))<sub>8</sub> (SEQ ID NO:18).

25. The polypeptide according to claim 7, which is 4-maleimidobutyl-Ala-(Tyr(PO<sub>3</sub>H<sub>2</sub>))<sub>5</sub>-β Ala (SEQ ID NO:18).


26. The combined product according to claim 7, wherein the spacer is a group represented by the following formula (VII), (VIII) or (IX):




wherein p is an integer of 1 to 10,

Amendment under 37 CFR §1.111  
IMAJO et al.

Divisional Application of 08/680,885  
Attorney Docket No: 960587A



wherein each of q and r is zero or an integer of 1 to 5,



wherein q and r are as defined above.